AC Immune SA (ACIU) vs Faeth Therapeutics (FTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed AC Immune SA (ACIU) over the past year, losing 9.6% versus a loss of 35.0%. Over five years, ACIU leads with a -62.3% price change compared with -95.0% for FTH. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $193.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | FTH |
|---|---|---|
| Share price | $1.95 | $7.88 |
| Market cap | $193.88M | $203.65M |
| 1-day change | -8.45% | -9.32% |
| YTD return | -37.90% | -26.15% |
| 1-year return | -35.00% | -9.64% |
| 5-year return | -62.28% | -94.96% |
| Forward P/E | 2.84 | — |
| EPS (TTM) | $-0.44 | $-22.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-21.09M |
| 52-week high | $3.90 | $42.14 |
| 52-week low | $1.93 | $7.45 |
| Distance from 52-week high | -50.00% | -81.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +331.28% | +612.56% |
| Average volume | 198.81K | 500.25K |
| Shares outstanding | 99.43M | 25.84M |
| Employees | 90 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed ACIU by 25.4 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ACIU vs FTH FAQ
Which is bigger, AC Immune SA or Faeth Therapeutics?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $193.88M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or FTH?
FTH returned -9.64% over the past 12 months, compared with -35.00% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Faeth Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.